People · Operator
Named in public records as an officer, director or promoter · active 2013–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OncoResponse Inc | — | Biotechnology | Series C | $109.0M | $39.4M | 2015 |
| ImmunoGenesis, Inc. | — | Biotechnology | Series C | $50.2M | $43.0M | 2024 |
| Cardiac Insight, Inc. | — | Biotechnology | Series A | $38.1M | $184.0M | 2019 |
| Theraclone Sciences, Inc. | — | Biotechnology | Series A | $36.7M | $111.3M | 2013 |
| K2 Biolabs, Inc. | — | Biotechnology | Series A | $6.1M | $5.4M | 2021 |
Clifford Stocks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Clifford Stocks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| Wende Hutton | 2 | 16 |
| TED KOUTOUZIS | 2 | 4 |
| Russ Hawkinson | 2 | 2 |
| Kristine Swiderek | 2 | 2 |
| Clifford J. Stocks | 2 | 2 |
| Andrew Perlman | 1 | 15 |
| Steve Gillis | 1 | 13 |
| Geeta Vemuri | 1 | 7 |
| Robert Stein | 1 | 6 |
| Christopher Mirabelli | 1 | 6 |
| William Greene | 1 | 6 |
| John McKearn | 1 | 6 |
| Robert B. Stein | 1 | 5 |
| Brad Harlow | 1 | 4 |
| Thomas Barton | 1 | 4 |
| Wendye Robbins | 1 | 3 |
| Bill Willis | 1 | 3 |
| Richard O Martin | 1 | 3 |
| Robert Odell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.